-
PATIENT-REPORTED OUTCOMES AFTER KIDNEY TRANSPLANTATION: REAL-WORLD EVIDENCE OF BURDEN POST-TRANSPLANT
Mar 6, 2026, 15:47 PM -
AGE AND GENDER-SPECIFIC DIMENSIONALITY OF THE SATISFACTION WITH LIFE SCALE
Mar 6, 2026, 15:47 PM -
HOW SOCIETY VALUES HEALTH: UNEQUAL CONTRIBUTIONS OF PHYSICAL AND MENTAL WELL-BEING TO SOCIAL WELFARE
Mar 6, 2026, 15:47 PM -
SF-6D POPULATION NORMS AND DISUTILITY WEIGHTS FOR SINGULAR AND CO-OCCURRING BEHAVIOURAL RISK FACTORS: EVIDENCE FROM TRADITIONAL AND MACHINE LEARNING MODELS
Mar 6, 2026, 15:47 PM -
UNCERTAINTY PROBABILITY THRESHOLDS AND INSUFFICIENT ITERATIONS OF PROBABILISTIC SENSITIVITY ANALYSIS IN ECONOMIC EVALUATION
Mar 6, 2026, 15:47 PM -
MODELLING HETEROGENEITY WITHOUT INDIVIDUAL SIMULATION: STRUCTURAL CHOICES AND SAMPLING STRATEGIES
Mar 6, 2026, 15:47 PM -
COMPARING THREE- AND FOUR-HEALTH-STATE SEMI-MARKOV MODELS DERIVED FROM A COMMON DISCRETE-EVENT SIMULATION IN EARLY-STAGE ONCOLOGY
Mar 6, 2026, 15:47 PM -
THE CE STAR: A NEW FIGURE TO ENHANCE ONE-WAY SENSITIVITY ANALYSES
Mar 6, 2026, 15:47 PM -
REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND COSTS OF HOSPITAL-ONSET METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS NON-VENTILATOR-ASSOCIATED PNEUMONIA IN U.S. HOSPITALS: 2023-2025
Mar 6, 2026, 15:46 PM -
REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY BY CISPLATIN ELIGIBILITY STATUS: A US MULTICENTER CHART REVIEW STUDY
Mar 6, 2026, 15:46 PM -
COMPARING THE RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS BETWEEN GABAPENTINOIDS AND DULOXETINE
Mar 6, 2026, 15:46 PM -
REAL-WORLD SAFETY PROFILE OF PEMBROLIZUMAB VS. NIVOLUMAB AND CETUXIMAB IN ADULTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA: A COMPARATIVE ANALYSIS
Mar 6, 2026, 15:46 PM -
MATERIAL HARDSHIP AND MULTI-CANCER SCREENING ADHERENCE: IMPLICATIONS BEYOND INSURANCE STATUS
Mar 6, 2026, 15:45 PM -
DISPARITY CONSIDERATIONS IN AN ALTERNATIVE ELIGIBILITY CRITERION FOR MEDICARE MEDICATION THERAPY MANAGEMENT PROGRAMS WITH MACHINE LEARNING
Mar 6, 2026, 15:45 PM -
NOT JUST GLP-1 COSTS: WHY LOWER DIABETES DRUG EXPENDITURES MAY NOT REFLECT BETTER CARE
Mar 6, 2026, 15:45 PM -
MAPPING ACCESS DESERTS: A GEOSPATIAL ASSESSMENT OF SOCIOECONOMIC DISPARITIES IN THE UNITED STATES DLBCL CAR-T THERAPY NETWORK
Mar 6, 2026, 15:45 PM -
GROWTH IN PRIVATE-PAYER MARKUPS FOR INFUSED CHEMOTHERAPY RELATIVE TO MEDICARE AVERAGE SALES PRICE BY SITE OF CARE, 2015-2023
Mar 6, 2026, 15:45 PM -
INTERNATIONAL AVAILABILITY AND PRICE OF ULTRA-EXPENSIVE DRUGS IN MEDICARE PART D: ASSESSING THE FEASIBILITY OF EXTERNAL REFERENCE PRICING
Mar 6, 2026, 15:45 PM -
SETTING EVIDENCE STANDARDS BEFORE SETTING INTERNATIONAL PRICE BENCHMARKS: INSIGHTS FROM EX-U.S. G7 HEALTH TECHNOLOGY ASSESSMENTS ON TOP-SPENDING U.S. MEDICARE PART B BIOLOGICS
Mar 6, 2026, 15:45 PM -
PROJECTED MEDICARE DRUG PRICE NEGOTIATION SAVINGS IN 2027
Mar 6, 2026, 15:45 PM
